Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend
RAFT-AF Extend
Randomized Ablation-based Atrial Fibrillation Rhythm-control Versus Rate-control Trial in Patients With Heart Failure and High-burden Atrial Fibrillation Extend
1 other identifier
observational
324
1 country
11
Brief Summary
This is an extended follow up study of the original RAFT-AF Study. The RAFT-AF study was a multi-centre randomized controlled trial with a prospective randomized open blinded endpoint trial (PROBE) design. Patients were randomized to either catheter ablation-based rhythm control of AF as compared to rate control of AF
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2023
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 6, 2021
CompletedFirst Posted
Study publicly available on registry
November 12, 2021
CompletedStudy Start
First participant enrolled
May 8, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2024
CompletedMarch 24, 2025
March 1, 2025
1.3 years
October 6, 2021
March 20, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Composite of mortality and Heart Failure Events
Death or HF Event ( admit \> 24 hrs or urgent out patient or ER visit for IV diuretics)
24 months
Secondary Outcomes (2)
all-cause mortality
24 months
Heart Failure Events
24 months
Study Arms (2)
Ablation-based rhythm-control
Ablation-based rhythm-control consisted of pulmonary vein isolation in paroxysmal atrial fibrillation, and additional ablation for persistent atrial fibrillation
Rate-control
Rate-control included AV-nodal blocking agents and AV node ablation with permanent pacing
Eligibility Criteria
All eligible patients enrolled in the original RAFT-AF Study
You may qualify if:
- All patients previously enrolled and randomized in the RAFT-AF Study that are eligible to enroll
You may not qualify if:
- Did not participate in the original RAFT-AF Study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Anthony Tanglead
Study Sites (11)
Libin Cardiovascular Institute
Calgary, Alberta, Canada
Victoria Cardiac Arrhythmia Trials
Victoria, British Columbia, Canada
Queen Elizabeth II Health Science
Halifax, Nova Scotia, Canada
Hamilton Health Sciences Centre
Hamilton, Ontario, Canada
Kingston General Hospital
Kingston, Ontario, Canada
St. Mary's General Hospital
Kitchener, Ontario, Canada
London Health Science Centre
London, Ontario, Canada
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
CHUS Le Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anthony Tang
London Health Sciences Research Institute
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor of Medicine, Western University
Study Record Dates
First Submitted
October 6, 2021
First Posted
November 12, 2021
Study Start
May 8, 2023
Primary Completion
August 30, 2024
Study Completion
August 30, 2024
Last Updated
March 24, 2025
Record last verified: 2025-03